Gideon Hirschfield

As the Lily and Terry Horner Chair in Autoimmune Liver Disease Research and Staff Hepatologist, Toronto Centre for Liver Disease, Toronto General Hospital and University of Toronto, working with a broad collaborative team of committed clinicians, scientists and co-ordinators, we seek to understand, manage and treat patients with immune/inflammatory mediated liver disease rationally, personally and effectively. To do so we bridge discovery science, clinical trials and development of risk-stratified clinical care pathways, in a manner embedded in national and international networks (IAIHG; IPSCSG; Global PBC Study Group, CaNAL), and with strong interaction with Industry and patients. My programme and interest has arisen from pivotal discoveries, and subsequent collaborative research, focused on genetic risk factors for the development of autoimmune liver disease (e.g. NEJM 2009; Nat Genet 2010; Nat Genet 2010; Nat Commun 2015, Gut 2018), with laboratory science focusing on mechanistic understanding of risk pathways in human liver tissue studies (e.g. Gastroenterology 2014; Hepatology 2016; J Hepatol 2016; Gut 2016; Gut 2018, J Autoimmune 2018; Hepatology Communications 2018). Utilising my strength in clinical Hepatology I have championed risk stratified care for patients (J Hepatol 2014; Gastroenterology 2014; Gastroenterology 2015; Gut 2016, Hepatology 2019) and built international credibility in delivery of clinical trials (Gastroenterology 2015; Hepatology 2016; NEJM 2016, J Hepatol 2019). Our group further continues to develop and implement a strong theme and belief in dissemination of knowledge to all, evolving the use of quality metrics to ensure all patients, and their families, are offered optimized, but research-driven, clinical management on a day-to-day basis.
See: https://www.ncbi.nlm.nih.gov/pubmed/?term=hirschfield+g ; @AutoImmuneLiver ; https://sites.google.com/view/global-hepatology-aild